Meanwhile, the research by Yang et al. (2023) [49] found that brigatinib did not show superiority over alectinib for PFS in patients with ALK-positive NSCLC previously treated with crizotinib, highlighting the consistent safety profiles of both drugs and reaffirming their positions as standard treatments post-crizotinib. Here, ALK is linked to non-small cell lung carcinoma.